A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
Eisai Inc.
NeoImmuneTech
Revolution Medicines, Inc.
Sichuan Enray Pharmaceutical Sciences Company
A2 Biotherapeutics Inc.
Essen Biotech
Essen Biotech
DualityBio Inc.
M.D. Anderson Cancer Center
Onchilles Pharma Inc
Ocellaris Pharma, Inc.
Eli Lilly and Company
GV20 Therapeutics
Krystal Biotech, Inc.
Eli Lilly and Company
Proton Collaborative Group
A2 Biotherapeutics Inc.
Palleon Pharmaceuticals, Inc.
NuCana plc
Turning Point Therapeutics, Inc.
PharmaMar
Marengo Therapeutics, Inc.
Cancer Research UK
Bristol-Myers Squibb
Cancer Research UK
Hoffmann-La Roche
Numab Therapeutics AG
Novartis
A2 Biotherapeutics Inc.
Xynomic Pharmaceuticals, Inc.
Intensity Therapeutics, Inc.
OncoResponse, Inc.
Cyteir Therapeutics, Inc.
Aminex Therapeutics, Inc.
Iovance Biotherapeutics, Inc.
Simcha IL-18, Inc.
Salubris Biotherapeutics Inc
GlaxoSmithKline
Cantargia AB
Cancer Research UK
University of California, San Diego
Mural Oncology, Inc
GlaxoSmithKline
Capital Medical University
Capital Medical University
CytomX Therapeutics
AstraZeneca
CytomX Therapeutics
Apexigen America, Inc.
OncoResponse, Inc.